Literature DB >> 9638440

Fibrolamellar hepatocellular carcinoma--an atypical MR manifestation.

M S Hui1, W M Choi, H L Perng, L K Chen, K C Yang, T J Chen.   

Abstract

We report the imaging findings, specifically magnetic resonance pictures of a non-cirrhotic case of fibrolamellar hepatocellular carcinoma in an older patient (60 years). Computed tomography revealed non-enhanced hypodense central scar without notable intratumoral calcification. MR imaging revealed a mass, which was homogeneously hypointense on T1-weighted images (T1WI) and turned hyperintense on T2-weighted images (T2WI). Stellate central scar was depicted with more hypointensity on T1WI, however, it became markedly hyperintense on T2WI. This manifestation is very different from the typical pattern reported in the literature. In gadolinium enhanced T1WI, the mass other than the central scar got enhanced. Fibronodular hyperplasia and fibrolamellar hepatocellular carcinoma should be differentiated with reference to the clinical and imaging findings. Collagenous central scar was described pathologically within the latter. However, a discrepancy between the pathological and magnetic resonance pattern concerning the central scar which was collagenous and corresponding to hyperintensity on T2WI was found. To our knowledge no similar entity has been described in the literatures so far.

Entities:  

Mesh:

Year:  1998        PMID: 9638440

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients.

Authors:  R K G Do; A McErlean; C S Ang; R P DeMatteo; G K Abou-Alfa
Journal:  Br J Radiol       Date:  2014-06-04       Impact factor: 3.039

Review 2.  Imaging findings of hepatic epithelioid hemangioendothelioma and fibrolamellar hepatocellular carcinoma: a critical appraisal of current literature about imaging features of two rare liver cancers.

Authors:  Lorenzo Mulazzani; Margherita Alvisi
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.